非嚢胞性線維症気管支拡張症市場-世界の産業規模、シェア、動向、機会、予測、治療別、診断別、最終用途別、地域別、競合別、2019～2029年

世界の非嚢胞性線維症気管支拡張症市場は、2023年に35億2,000万米ドルと評価され、2029年までのCAGRは5.25%で、予測期間中に目覚ましい成長を遂げると予測されています。

非嚢胞性線維性気管支拡張症（NCFB）は、気道の異常な拡大と瘢痕化を特徴とする慢性呼吸器疾患で、粘液の蓄積と呼吸器感染症の再発を引き起こします。世界のNCFB市場は、認知度の向上、診断法の改善、革新的な治療法により成長を遂げています。有病率の増加、医療専門家の意識の向上、診断の進歩などの要因がこの成長を後押ししています。気管支拡張症はあらゆる年齢層に発症し、世界的に公衆衛生上の関心が高まっています。高解像度コンピュータ断層撮影（HRCT）スキャンのような高度な診断ツールは診断精度を高め、タイムリーな治療を可能にしています。教育イニシアティブやアドボカシー活動により、医療プロバイダーや患者の意識が高まり、早期介入につながっています。さらに、吸入抗生物質や粘液溶解剤などの新しい治療法の開発により、より効果的な解決策が提供されています。世界人口の高齢化に伴い、NCFBの罹患率は上昇し、市場の拡大をさらに促すと予測されます。

主要市場の促進要因

疾患有病率の上昇が世界の非嚢胞性線維症気管支拡張症市場を牽引

進化する政府の取り組みと資金援助が世界の非嚢胞性線維症気管支拡張症市場を牽引

主要市場課題

限られた認知度と診断

限られた治療オプション

高い治療費

主要市場動向

技術の進歩

セグメント別洞察

治療別洞察

最終用途別洞察

地域別洞察

目次

第1章 概要

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 非嚢胞性線維症気管支拡張症の世界市場展望

• 市場規模予測
  • 金額別
• 市場シェア予測
  • 治療別（手術、理学療法、ワクチン接種、気道薬剤療法、抗生物質、その他）
  • 診断別（CTスキャン、気管支鏡、胸部X線、肺機能、喀痰培養試験、血液試験、その他）
  • 用途別（病院、クリニック、外来、その他）
  • 地域別
  • 企業別（2023年）
• 市場マップ
  • 治療別
  • 診断別
  • 最終用途別
  • 地域別

第5章 アジア太平洋の非嚢胞性線維症気管支拡張症市場展望

• 市場規模予測
  • 金額別
• 市場シェア予測
  • 治療別
  • 診断別
  • 最終用途別
  • 国別
• アジア太平洋：国別分析
  • 中国
  • インド
  • オーストラリア
  • 日本
  • 韓国

第6章 欧州の非嚢胞性線維症気管支拡張症市場展望

• 市場規模予測
  • 金額別
• 市場シェア予測
  • 治療別
  • 診断別
  • 最終用途別
  • 国別
• 欧州：国別分析
  • フランス
  • ドイツ
  • スペイン
  • イタリア
  • 英国

第7章 北米の非嚢胞性線維症気管支拡張症市場展望

• 市場規模予測
  • 金額別
• 市場シェア予測
  • 治療別
  • 診断別
  • 最終用途別
  • 国別
• 北米：国別分析
  • 米国
  • メキシコ
  • カナダ

第8章 南米の非嚢胞性線維症気管支拡張症市場展望

• 市場規模予測
  • 金額別
• 市場シェア予測
  • 治療別
  • 診断別
  • 最終用途別
  • 国別
• 南米：国別分析
  • ブラジル
  • アルゼンチン
  • コロンビア

第9章 中東・アフリカの非嚢胞性線維症気管支拡張症市場展望

• 市場規模予測
  • 金額別
• 市場シェア予測
  • 治療別
  • 診断別
  • 最終用途別
  • 国別
• 中東・アフリカ：国別分析
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦

第10章 市場力学

• 促進要因
• 課題

第11章 市場動向と新興国市場開拓

• 製品発表
• 合併・買収

第12章 世界の非嚢胞性線維症気管支拡張症市場のSWOT分析

第13章 ポーターのファイブフォース分析

• 業界内の競合
• 新規参入の可能性
• サプライヤーの力
• 顧客の力
• 代替品の脅威

第14章 競合情勢

• Novartis AG
• Pfizer Inc.
• Bayer AG
• Viatris Inc.
• Teva Pharmaceutical Industries Ltd.
• GSK plc
• F. Hoffmann-La Roche Ltd.
• Sun Pharmaceutical Industries Ltd.
• Aurobindo Pharma Ltd.
• Dr. Reddy's Laboratories Ltd.

第15章 戦略的提言

第16章 戦略的提言当社について免責事項

Global Non-Cystic Fibrosis Bronchiectasis Marketwas valued at USD 3.52 Billion in 2023 and is anticipated to project steady growth in the forecast period with a CAGR of 5.25% through 2029.Non-cystic fibrosis bronchiectasis (NCFB) presents a chronic respiratory ailment characterized by abnormal widening and scarring of airways, leading to mucus buildup and recurrent respiratory infections. The global NCFB market is experiencing growth due to heightened awareness, improved diagnostics, and innovative treatments. Factors such as increased disease prevalence, better healthcare professional awareness, and diagnostic advancements are propelling this growth. Bronchiectasis affects all age groups and is a growing public health concern globally. Advanced diagnostic tools like high-resolution computed tomography (HRCT) scans have enhanced diagnosis accuracy, allowing for timely treatment. Rising awareness among healthcare providers and patients, driven by educational initiatives and advocacy, results in earlier intervention. In addition, the development of new therapies such as inhaled antibiotics and mucolytics offers more effective solutions. With the aging global population, NCFB incidence is projected to escalate, further stimulating market expansion.

Key Market Drivers

Rising Disease Prevalence is Driving the Global Non-Cystic Fibrosis Bronchiectasis Market

Non-Cystic Fibrosis Bronchiectasis (NCFB) is a chronic respiratory condition characterized by bronchial tube widening and inflammation in the lungs. Despite historically receiving less attention than other lung diseases like asthma or chronic obstructive pulmonary disease (COPD), the global NCFB market is gaining momentum due to a significant uptick in disease prevalence. This surge in cases has spurred research, development, and innovation in the pharmaceutical and healthcare sectors, propelling the growth of the global NCFB market.

The increasing prevalence of NCFB globally poses a notable public health concern. Several factors contribute to this rise in disease prevalence. With the global population aging, the risk of developing NCFB escalates, particularly among individuals over 50 years old, contributing to the growing number of cases. Advancements in medical technology and diagnostic methods have facilitated easier identification of NCFB, resulting in more accurate and timely diagnoses. Consequently, more cases are being reported and treated, with heightened awareness among healthcare professionals and the public leading to increased recognition and reporting rates.

The expanding prevalence of NCFB has significantly impacted the global NCFB market, encompassing a variety of products and services including medications, therapies, and diagnostic tools for managing and treating the condition. Pharmaceutical companies are increasingly investing in research and development to develop effective medications for NCFB aimed at alleviating symptoms, controlling infections, and enhancing patients' quality of life. Progress in diagnostic tools like high-resolution computed tomography (HRCT) scans facilitates NCFB detection, aiding in early diagnosis and treatment. Emerging treatment modalities such as airway clearance techniques and nebulizers are aiding symptom management and patient well-being. Likewise, personalized treatment approaches like inhaled antibiotics and bronchodilators are being explored to address specific patient needs. Ongoing research and clinical trials are expanding understanding of NCFB and offering insights into more effective treatments, potentially leading to breakthrough innovations. Increased awareness and patient education initiatives are fostering better disease management, treatment adherence, and improved patient outcomes.

Evolving Government Initiatives and Funding is Driving the Global Non-Cystic Fibrosis Bronchiectasis Market

Governments worldwide are increasingly acknowledging the necessity of tackling Non-Cystic Fibrosis Bronchiectasis (NCFB) and have been actively implementing measures to enhance the well-being of affected individuals. Public health campaigns are being launched to raise awareness about NCFB, its risk factors, and the importance of early diagnosis, aiming to prompt individuals to seek medical attention sooner for earlier intervention. Substantial resources are being allocated by governments towards NCFB research, with grants supporting studies focused on understanding the disease's mechanisms, enhancing diagnostic methods, and developing innovative treatments. This funding enables researchers to explore new avenues and potential therapies for NCFB.

Governments are committed to ensuring that individuals with NCFB have access to affordable and high-quality healthcare. This involves subsidizing medications, promoting pulmonary rehabilitation programs, and facilitating regular check-ups to effectively manage the condition. Collaborations between governments, pharmaceutical companies, and healthcare providers are increasing to expedite the development and availability of novel therapies for NCFB.

The impact of government initiatives and funding on the NCFB market is substantial. The global NCFB market is experiencing notable growth, driven by various factors. Increased government funding has empowered pharmaceutical companies to invest in the development of new drugs and therapies, leading to the introduction of innovative treatments with the potential to enhance the lives of NCFB patients. Government support has also spurred advancements in diagnostic methods, resulting in earlier and more accurate detection of NCFB, which is crucial for effective management. The heightened focus on NCFB research has yielded therapies targeting the root causes of the condition, aiming to alleviate symptoms, reduce disease progression, and improve patients' quality of life. Government funding and support have fostered the expansion of the NCFB market, including the production of medications, medical devices, and services tailored to NCFB patients, thereby broadening the range of treatment options available.

While government initiatives and funding have played a pivotal role in propelling the global NCFB market, challenges persist. These include the high cost of research and development, market access issues, and the necessity for increased global collaboration. Nevertheless, the future outlook for NCFB management appears promising. With sustained government support, heightened research endeavors, and advancements in healthcare technology, the prospects for NCFB patients are expected to improve. As governments worldwide recognize the importance of addressing this escalating health concern, the NCFB market is poised for significant growth and innovation.

Key Market Challenges

Limited Awareness and Diagnosis

One of the most significant challenges in the NCFB market is the lack of awareness about the condition. Many individuals suffering from NCFB remain undiagnosed or are misdiagnosed, leading to delayed treatment and worsening of symptoms. Raising awareness among both healthcare professionals and the general public is crucial to ensure early diagnosis and appropriate management.Initiatives such as public health campaigns and medical education programs can help improve awareness and knowledge about NCFB. These efforts can facilitate early diagnosis and timely intervention.

Limited Treatment Options

Compared to other respiratory conditions, NCFB has a limited range of treatment options. Patients often rely on antibiotics, bronchodilators, and airway clearance techniques to manage their symptoms. The absence of disease-modifying therapies presents a significant challenge for healthcare providers and patients.Research and development in NCFB-focused pharmaceuticals should be encouraged. The development of innovative drugs that target the underlying causes of NCFB could potentially revolutionize the treatment landscape.

High Treatment Costs

Managing NCFB can be expensive, with costs associated with medication, hospitalizations, and ongoing medical care. This financial burden can be particularly challenging for patients, especially in regions with limited access to healthcare resources.Advocacy for affordable and accessible healthcare is essential. Health systems and governments should work to ensure that NCFB patients have access to cost-effective treatments and support programs.

Key Market Trends

Technological Advancements

The healthcare sector is continually advancing, driven by technological innovations and progressive research. A notable area witnessing this evolution is the treatment and management of non-cystic fibrosis bronchiectasis (NCFB). NCFB, a chronic and progressive lung condition affecting bronchial tubes, manifests symptoms such as chronic cough, excessive mucus production, and recurrent infections. The ongoing progress in medical technology significantly influences the global NCFB market.

Advancements in telemedicine and remote monitoring technologies are revolutionizing patient care. These innovations facilitate easier access to healthcare professionals and enable patients to manage their condition remotely. Through digital platforms, patients can connect with healthcare providers, share health data, and receive real-time guidance, reducing the necessity for frequent in-person visits. As well, technological progress in drug development has resulted in more effective NCFB treatments. Emerging medications, including inhaled antibiotics and mucolytics, demonstrate promise in symptom reduction and exacerbation prevention, potentially reshaping NCFB management with more efficient and convenient options.

Genomic and biomarker research advancements enable personalized treatment approaches for NCFB patients. By analyzing individual genetic profiles and specific biomarkers, healthcare providers can customize treatment strategies to meet each patient's distinct needs. This precision medicine approach enhances therapy effectiveness while minimizing adverse effects.Mobile applications, online support communities, and patient education platforms facilitate NCFB information access, experience sharing, and treatment plan involvement. Technological tools empower patients to proactively manage their condition, leading to improved outcomes and enhanced quality of life.

Segmental Insights

Treatment Insights

Basedon the category of Treatment, surgery emerged as the dominant player in the global market for Non-Cystic Fibrosis Bronchiectasis in 2023.In severe cases of Non-Cystic Fibrosis Bronchiectasis (NCFB), when a specific lung section is severely damaged and unresponsive to other therapies, surgical resection may be necessary. Surgeons remove the damaged lung portion, enabling the remaining healthy tissue to operate more efficiently. A less invasive surgical approach involves the insertion of endobronchial valves. These valves, operating in one direction, block airways leading to damaged lung tissue, redirecting airflow to healthier areas. This procedure can enhance lung function and improve patients' quality of life. Bronchial thermoplasty is an innovative procedure delivering controlled thermal energy to airway walls, reducing excessive smooth muscle in the bronchi. This treatment can alleviate bronchospasm and enhance airway function in NCFB patients. Surgical interventions also address NCFB complications like bronchial strictures or obstructions. Procedures aimed at clearing or widening airways can significantly enhance breathing and quality of life.

End use Insights

TheHospitals Clinicssegment is projected to experience rapid growth during the forecast period.Early diagnosis and intervention play a pivotal role in effectively managing Non-Cystic Fibrosis Bronchiectasis (NCFB). Hospitals and clinics serve as primary points of contact for patients exhibiting respiratory symptoms, making them integral in the timely identification of NCFB cases. Physicians and pulmonologists in these healthcare facilities possess the requisite tools and expertise to diagnose NCFB through a combination of clinical assessment, imaging studies (such as high-resolution computed tomography or HRCT), and pulmonary function tests. Besides, the establishment of specialized respiratory clinics within hospitals has enhanced diagnostic accuracy and timeliness. Early identification and treatment of NCFB not only enhance patients' quality of life but also mitigate healthcare costs associated with managing advanced disease stages.

Hospitals and clinics lead the forefront in NCFB management, offering a diverse array of treatment modalities. These facilities provide access to healthcare professionals specializing in respiratory medicine, ensuring personalized care for patients. Treatment approaches for NCFB encompass bronchodilators, mucus-thinning medications, antibiotics, and, when necessary, surgical interventions for lung tissue removal. In addition, hospitals often host pulmonary rehabilitation programs tailored to improve lung function, enhance exercise capacity, and educate patients on symptom management. The provision of requisite infrastructure and personnel support for these programs underscores hospitals' and clinics' significant contributions to the overall well-being of NCFB patients.

Regional Insights

North America emerged as the dominant player in the global Non-Cystic Fibrosis Bronchiectasis market in 2023, holding the largest market share in terms of value. The region hosts numerous clinical trials, funded research, and academic institutions dedicated to NCFB. These studies aim to understand the pathophysiology of the disease, develop novel therapies, and improve diagnosis and management.North America has seen a surge in pharmaceutical companies investing in the development of new therapies for NCFB. This has led to the introduction of innovative treatments that target the underlying causes of the disease and improve the quality of life for patients.Patient advocacy groups in North America have played a pivotal role in raising awareness about NCFB and advocating for better care and support for those affected by the condition. They work to ensure that patients have access to the latest treatments and information.

Key Market Players

Novartis AG

Pfizer Inc.

Bayer AG

Viatris Inc.

Teva Pharmaceutical Industries Ltd.

GSK plc

F. Hoffmann-La Roche Ltd.

Sun Pharmaceutical Industries Ltd.

Aurobindo Pharma Ltd.

Dr. Reddy's Laboratories Ltd.

Report Scope:

In this report, the GlobalNon-Cystic Fibrosis BronchiectasisMarket has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Non-Cystic Fibrosis Bronchiectasis Market,By Treatment:

• Surgery
• Physiotherapy
• Vaccination
• Airway Pharmacotherapy
• Antibiotics
• Others

Non-Cystic Fibrosis Bronchiectasis Market,By Diagnosis:

• CT scan
• Bronchoscopy
• Chest X-ray
• Lung function
• Sputum culture test
• Blood Tests
• Others

Non-Cystic Fibrosis Bronchiectasis Market,By End use:

• Hospitals Clinics
• Ambulatory Care Centers
• Others

Non-Cystic Fibrosis Bronchiectasis Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Non-Cystic Fibrosis Bronchiectasis Market.

Available Customizations:

Global Non-Cystic Fibrosis Bronchiectasis market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1.Product Overview

• 1.1.Market Definition
• 1.2.Scope of the Market
  • 1.2.1.Markets Covered
  • 1.2.2.Years Considered for Study
  • 1.2.3.Key Market Segmentations

2.Research Methodology

• 2.1.Objective of the Study
• 2.2.Baseline Methodology
• 2.3.Key Industry Partners
• 2.4.Major Association and Secondary Sources
• 2.5.Forecasting Methodology
• 2.6.Data Triangulation Validation
• 2.7.Assumptions and Limitations

3.Executive Summary

• 3.1.Overview of the Market
• 3.2.Overview of Key Market Segmentations
• 3.3.Overview of Key Market Players
• 3.4.Overview of Key Regions/Countries
• 3.5.Overview of Market Drivers, Challenges, Trends

4.Global Non-Cystic Fibrosis Bronchiectasis Market Outlook

• 4.1.Market Size Forecast
  • 4.1.1.By Value
• 4.2.Market Share Forecast
  • 4.2.1.By Treatment (Surgery, Physiotherapy, Vaccination, Airway Pharmacotherapy, Antibiotics, Others)
  • 4.2.2.By Diagnosis (CT scan, Bronchoscopy, Chest X-ray, Lung Function, Sputum Culture Test, Blood Tests, Others)
  • 4.2.3.By End use (Hospitals Clinics, Ambulatory Care Centers, Others)
  • 4.2.4.By Region
  • 4.2.5.By Company (2023)
• 4.3.Market Map
  • 4.3.1.By Treatment
  • 4.3.2.By Diagnosis
  • 4.3.3.By End use
  • 4.3.4.By Region

5.Asia Pacific Non-Cystic Fibrosis Bronchiectasis Market Outlook

• 5.1.Market Size Forecast
  • 5.1.1.By Value
• 5.2.Market Share Forecast
  • 5.2.1.By Treatment
  • 5.2.2.By Diagnosis
  • 5.2.3.By End use
  • 5.2.4.By Country
• 5.3.Asia Pacific: Country Analysis
  • 5.3.1.China Non-Cystic Fibrosis Bronchiectasis Market Outlook
    • 5.3.1.1.Market Size Forecast
      • 5.3.1.1.1.By Value
    • 5.3.1.2.Market Share Forecast
      • 5.3.1.2.1.By Treatment
      • 5.3.1.2.2.By Diagnosis
      • 5.3.1.2.3.By End use
  • 5.3.2.India Non-Cystic Fibrosis Bronchiectasis Market Outlook
    • 5.3.2.1.Market Size Forecast
      • 5.3.2.1.1.By Value
    • 5.3.2.2.Market Share Forecast
      • 5.3.2.2.1.By Treatment
      • 5.3.2.2.2.By Diagnosis
      • 5.3.2.2.3.By End use
  • 5.3.3.Australia Non-Cystic Fibrosis Bronchiectasis Market Outlook
    • 5.3.3.1.Market Size Forecast
      • 5.3.3.1.1.By Value
    • 5.3.3.2.Market Share Forecast
      • 5.3.3.2.1.By Treatment
      • 5.3.3.2.2.By Diagnosis
      • 5.3.3.2.3.By End use
  • 5.3.4.Japan Non-Cystic Fibrosis Bronchiectasis Market Outlook
    • 5.3.4.1.Market Size Forecast
      • 5.3.4.1.1.By Value
    • 5.3.4.2.Market Share Forecast
      • 5.3.4.2.1.By Treatment
      • 5.3.4.2.2.By Diagnosis
      • 5.3.4.2.3.By End use
  • 5.3.5.South Korea Non-Cystic Fibrosis Bronchiectasis Market Outlook
    • 5.3.5.1.Market Size Forecast
      • 5.3.5.1.1.By Value
    • 5.3.5.2.Market Share Forecast
      • 5.3.5.2.1.By Treatment
      • 5.3.5.2.2.By Diagnosis
      • 5.3.5.2.3.By End use

6.Europe Non-Cystic Fibrosis Bronchiectasis Market Outlook

• 6.1.Market Size Forecast
  • 6.1.1.By Value
• 6.2.Market Share Forecast
  • 6.2.1.By Treatment
  • 6.2.2.By Diagnosis
  • 6.2.3.By End use
  • 6.2.4.By Country
• 6.3.Europe: Country Analysis
  • 6.3.1.France Non-Cystic Fibrosis Bronchiectasis Market Outlook
    • 6.3.1.1.Market Size Forecast
      • 6.3.1.1.1.By Value
    • 6.3.1.2.Market Share Forecast
      • 6.3.1.2.1.By Treatment
      • 6.3.1.2.2.By Diagnosis
      • 6.3.1.2.3.By End use
  • 6.3.2.Germany Non-Cystic Fibrosis Bronchiectasis Market Outlook
    • 6.3.2.1.Market Size Forecast
      • 6.3.2.1.1.By Value
    • 6.3.2.2.Market Share Forecast
      • 6.3.2.2.1.By Treatment
      • 6.3.2.2.2.By Diagnosis
      • 6.3.2.2.3.By End use
  • 6.3.3.Spain Non-Cystic Fibrosis Bronchiectasis Market Outlook
    • 6.3.3.1.Market Size Forecast
      • 6.3.3.1.1.By Value
    • 6.3.3.2.Market Share Forecast
      • 6.3.3.2.1.By Treatment
      • 6.3.3.2.2.By Diagnosis
      • 6.3.3.2.3.By End use
  • 6.3.4.Italy Non-Cystic Fibrosis Bronchiectasis Market Outlook
    • 6.3.4.1.Market Size Forecast
      • 6.3.4.1.1.By Value
    • 6.3.4.2.Market Share Forecast
      • 6.3.4.2.1.By Treatment
      • 6.3.4.2.2.By Diagnosis
      • 6.3.4.2.3.By End use
  • 6.3.5.United Kingdom Non-Cystic Fibrosis Bronchiectasis Market Outlook
    • 6.3.5.1.Market Size Forecast
      • 6.3.5.1.1.By Value
    • 6.3.5.2.Market Share Forecast
      • 6.3.5.2.1.By Treatment
      • 6.3.5.2.2.By Diagnosis
      • 6.3.5.2.3.By End use

7.North America Non-Cystic Fibrosis Bronchiectasis Market Outlook

• 7.1.Market Size Forecast
  • 7.1.1.By Value
• 7.2.Market Share Forecast
  • 7.2.1.By Treatment
  • 7.2.2.By Diagnosis
  • 7.2.3.By End use
  • 7.2.4.By Country
• 7.3.North America: Country Analysis
  • 7.3.1.United States Non-Cystic Fibrosis Bronchiectasis Market Outlook
    • 7.3.1.1.Market Size Forecast
      • 7.3.1.1.1.By Value
    • 7.3.1.2.Market Share Forecast
      • 7.3.1.2.1.By Treatment
      • 7.3.1.2.2.By Diagnosis
      • 7.3.1.2.3.By End use
  • 7.3.2.Mexico Non-Cystic Fibrosis Bronchiectasis Market Outlook
    • 7.3.2.1.Market Size Forecast
      • 7.3.2.1.1.By Value
    • 7.3.2.2.Market Share Forecast
      • 7.3.2.2.1.By Treatment
      • 7.3.2.2.2.By Diagnosis
      • 7.3.2.2.3.By End use
  • 7.3.3.Canada Non-Cystic Fibrosis Bronchiectasis Market Outlook
    • 7.3.3.1.Market Size Forecast
      • 7.3.3.1.1.By Value
    • 7.3.3.2.Market Share Forecast
      • 7.3.3.2.1.By Treatment
      • 7.3.3.2.2.By Diagnosis
      • 7.3.3.2.3.By End use

8.South America Non-Cystic Fibrosis Bronchiectasis Market Outlook

• 8.1.Market Size Forecast
  • 8.1.1.By Value
• 8.2.Market Share Forecast
  • 8.2.1.By Treatment
  • 8.2.2.By Diagnosis
  • 8.2.3.By End use
  • 8.2.4.By Country
• 8.3.South America: Country Analysis
  • 8.3.1.Brazil Non-Cystic Fibrosis Bronchiectasis Market Outlook
    • 8.3.1.1.Market Size Forecast
      • 8.3.1.1.1.By Value
    • 8.3.1.2.Market Share Forecast
      • 8.3.1.2.1.By Treatment
      • 8.3.1.2.2.By Diagnosis
      • 8.3.1.2.3.By End use
  • 8.3.2.Argentina Non-Cystic Fibrosis Bronchiectasis Market Outlook
    • 8.3.2.1.Market Size Forecast
      • 8.3.2.1.1.By Value
    • 8.3.2.2.Market Share Forecast
      • 8.3.2.2.1.By Treatment
      • 8.3.2.2.2.By Diagnosis
      • 8.3.2.2.3.By End use
  • 8.3.3.Colombia Non-Cystic Fibrosis Bronchiectasis Market Outlook
    • 8.3.3.1.Market Size Forecast
      • 8.3.3.1.1.By Value
    • 8.3.3.2.Market Share Forecast
      • 8.3.3.2.1.By Treatment
      • 8.3.3.2.2.By Diagnosis
      • 8.3.3.2.3.By End use

9.Middle East and Africa Non-Cystic Fibrosis Bronchiectasis Market Outlook

• 9.1.Market Size Forecast
  • 9.1.1.By Value
• 9.2.Market Share Forecast
  • 9.2.1.By Treatment
  • 9.2.2.By Diagnosis
  • 9.2.3.By End use
  • 9.2.4.By Country
• 9.3.MEA: Country Analysis
  • 9.3.1.South Africa Non-Cystic Fibrosis Bronchiectasis Market Outlook
    • 9.3.1.1.Market Size Forecast
      • 9.3.1.1.1.By Value
    • 9.3.1.2.Market Share Forecast
      • 9.3.1.2.1.By Treatment
      • 9.3.1.2.2.By Diagnosis
      • 9.3.1.2.3.By End use
  • 9.3.2.Saudi Arabia Non-Cystic Fibrosis Bronchiectasis Market Outlook
    • 9.3.2.1.Market Size Forecast
      • 9.3.2.1.1.By Value
    • 9.3.2.2.Market Share Forecast
      • 9.3.2.2.1.By Treatment
      • 9.3.2.2.2.By Diagnosis
      • 9.3.2.2.3.By End use
  • 9.3.3.UAE Non-Cystic Fibrosis Bronchiectasis Market Outlook
    • 9.3.3.1.Market Size Forecast
      • 9.3.3.1.1.By Value
    • 9.3.3.2.Market Share Forecast
      • 9.3.3.2.1.By Treatment
      • 9.3.3.2.2.By Diagnosis
      • 9.3.3.2.3.By End use

10.Market Dynamics

• 10.1.Drivers
• 10.2.Challenges

11.Market Trends Developments

• 11.1.Recent Developments
• 11.2.Product Launches
• 11.3.Mergers Acquisitions

12.Global Non-Cystic Fibrosis Bronchiectasis Market: SWOT Analysis

13.Porter's Five Forces Analysis

• 13.1.Competition in the Industry
• 13.2.Potential of New Entrants
• 13.3.Power of Suppliers
• 13.4.Power of Customers
• 13.5.Threat of Substitute Product

14.Competitive Landscape

• 14.1.Novartis AG
  • 14.1.1.Business Overview
  • 14.1.2.Company Snapshot
  • 14.1.3.Product Services
  • 14.1.4.Financials (In case of listed)
  • 14.1.5.Recent Developments
  • 14.1.6.SWOT Analysis
• 14.2.Pfizer Inc.
• 14.3.Bayer AG
• 14.4.Viatris Inc.
• 14.5.Teva Pharmaceutical Industries Ltd.
• 14.6.GSK plc
• 14.7.F. Hoffmann-La Roche Ltd.
• 14.8.Sun Pharmaceutical Industries Ltd.
• 14.9.Aurobindo Pharma Ltd.
• 14.10.Dr. Reddy's Laboratories Ltd.

15.Strategic Recommendations

16. About Us Disclaimer